Akari Therapeutics, Plc
AKTX
$1.12
-$0.03-2.61%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -26.90% | 18.09% | -39.42% | -27.50% | 29.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -41.14% | -15.62% | -26.13% | 20.37% | 30.37% |
| Operating Income | 41.14% | 15.62% | 26.13% | -20.37% | -30.37% |
| Income Before Tax | 33.44% | 8.84% | -0.84% | -88.95% | -656.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 33.44% | 8.84% | -0.84% | -88.95% | -656.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 33.44% | 8.84% | -0.84% | -88.95% | -656.04% |
| EBIT | 41.14% | 15.62% | 26.13% | -20.37% | -30.37% |
| EBITDA | 41.07% | 15.62% | 26.10% | -20.39% | -30.11% |
| EPS Basic | 83.60% | 79.33% | 58.17% | -1.47% | -409.00% |
| Normalized Basic EPS | 83.35% | 84.73% | 73.70% | 23.95% | -408.96% |
| EPS Diluted | 83.60% | 79.33% | 58.17% | -1.47% | -413.09% |
| Normalized Diluted EPS | 83.35% | 84.73% | 73.70% | 23.95% | -413.08% |
| Average Basic Shares Outstanding | 305.76% | 341.21% | 141.04% | 86.22% | 79.99% |
| Average Diluted Shares Outstanding | 312.12% | 361.90% | 140.00% | 88.00% | 83.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |